Natural history of HLA expression during tumour development - PubMed (original) (raw)
Review
Natural history of HLA expression during tumour development
F Garrido et al. Immunol Today. 1993 Oct.
Abstract
HLA expression is frequently altered in tumours compared to the tissue from which they originate. Given the central role of MHC products in the restriction of T-cell recognition, regulation of tumour HLA expression might be a strategy for the evasion of immune surveillance by the malignant cells. Federico Garrido, Peter Stern and colleagues present data from a variety of tumour types, suggesting that HLA class I alterations may occur at a particular step between the development of an in situ lesion and an invasive carcinoma.
Similar articles
- Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?
Wischhusen J, Waschbisch A, Wiendl H. Wischhusen J, et al. Semin Cancer Biol. 2007 Dec;17(6):459-68. doi: 10.1016/j.semcancer.2007.07.005. Epub 2007 Jul 31. Semin Cancer Biol. 2007. PMID: 17768067 Review. - The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P, Hämmerling GJ. Möller P, et al. Cancer Surv. 1992;13:101-27. Cancer Surv. 1992. PMID: 1423320 Review. - Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer.
Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C, Valvassori L, Mordoh J. Levy EM, et al. Int J Oncol. 2008 Mar;32(3):633-41. Int J Oncol. 2008. PMID: 18292941 - The biological consequences of altered MHC class I expression in tumours.
Algarra I, Gaforio JJ, Cabrera T, Collado A, Garrido F. Algarra I, et al. J Biol Regul Homeost Agents. 1999 Apr-Jun;13(2):90-6. J Biol Regul Homeost Agents. 1999. PMID: 10503731 Review. - Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.
Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, Stern PL. Garrido F, et al. Immunol Today. 1997 Feb;18(2):89-95. doi: 10.1016/s0167-5699(96)10075-x. Immunol Today. 1997. PMID: 9057360 Review.
Cited by
- Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines.
Méndez R, Rodríguez T, Del Campo A, Monge E, Maleno I, Aptsiauri N, Jiménez P, Pedrinaci S, Pawelec G, Ruiz-Cabello F, Garrido F. Méndez R, et al. Cancer Immunol Immunother. 2008 May;57(5):719-29. doi: 10.1007/s00262-007-0411-3. Epub 2007 Oct 13. Cancer Immunol Immunother. 2008. PMID: 17934731 Free PMC article. - Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine.
Hajtó T, Fodor K, Perjési P, Németh P. Hajtó T, et al. Evid Based Complement Alternat Med. 2011;2011:298972. doi: 10.1093/ecam/nep191. Epub 2011 Jan 9. Evid Based Complement Alternat Med. 2011. PMID: 19939951 Free PMC article. - Cavitation-Mediated Immunomodulation and Its Use with Checkpoint Inhibitors.
Maardalen M, Carlisle R, Coussios C. Maardalen M, et al. Pharmaceutics. 2023 Aug 9;15(8):2110. doi: 10.3390/pharmaceutics15082110. Pharmaceutics. 2023. PMID: 37631324 Free PMC article. Review. - B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.
Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. Azuma T, et al. Blood. 2008 Apr 1;111(7):3635-43. doi: 10.1182/blood-2007-11-123141. Epub 2008 Jan 25. Blood. 2008. PMID: 18223165 Free PMC article. - Acquisition of Ly49 receptor expression by developing natural killer cells.
Dorfman JR, Raulet DH. Dorfman JR, et al. J Exp Med. 1998 Feb 16;187(4):609-18. doi: 10.1084/jem.187.4.609. J Exp Med. 1998. PMID: 9463411 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials